By Amina Niasse
NEW YORK, Aug 25 (Reuters) - About 14% of employers in the United States have already or plan to drop GLP-1 drugs in 2027, as companies see rising healthcare costs, according to a survey released on Tuesday by the Business Group on Health.
Healthcare costs are set to increase 9.2% if employers do not make changes to manage costs in 2027, up from 8.5% in 2026, the group said. Two-thirds of employers surveyed said they saw rising utilization of the drugs.
GLP-1 weight-loss drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo, help people lose weight by mimicking a hormone that keeps the stomach feeling full. Zepbound and Wegovy cost $499 and $1,349.02, respectively, per month according to list prices on manufacturer websites.
"This represents an unfortunate new reality for employers, who now face growing difficulty in budgeting and forecasting," said Ellen Kelsay, president of the Business Group on Health. "It's a call to take a more disruptive approach and rethink how to deliver value and improved health outcomes."
#group #drugs
NEW YORK, Aug 25 (Reuters) - About 14% of employers in the United States have already or plan to drop GLP-1 drugs in 2027, as companies see rising healthcare costs, according to a survey released on Tuesday by the Business Group on Health.
Healthcare costs are set to increase 9.2% if employers do not make changes to manage costs in 2027, up from 8.5% in 2026, the group said. Two-thirds of employers surveyed said they saw rising utilization of the drugs.
GLP-1 weight-loss drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo, help people lose weight by mimicking a hormone that keeps the stomach feeling full. Zepbound and Wegovy cost $499 and $1,349.02, respectively, per month according to list prices on manufacturer websites.
"This represents an unfortunate new reality for employers, who now face growing difficulty in budgeting and forecasting," said Ellen Kelsay, president of the Business Group on Health. "It's a call to take a more disruptive approach and rethink how to deliver value and improved health outcomes."
#group #drugs
3 days ago
